In development. Features, timelines and partnership models are subject to final settings and approvals. Figures marked as targets are indicative.
The translation gap · Australia · 2024
Women's Health Foundry is being built by Proto Axiom to close the translation gap — specialist de-risking, milestone-gated capital, and partner pathways for Australian women's health ventures.
Where the gap lands
% of national total
Endometriosis
15× gap
Menopause & midlife
13× gap
Maternal health
5× gap
Cardiometabolic (women)
6× gap
Illustrative, derived from AIHW burden-of-disease + NHMRC/MRFF allocations, FY2023–24.
The gap
Across conditions that disproportionately affect women, disease burden routinely outruns research investment. The gap compounds down the pipeline: fewer programs, fewer clinical assets, fewer approvals.
Representative selection. Illustrative ranges derived from NHMRC, MRFF and AIHW datasets + Temkin et al. (2023). Ratios rounded.
The $7.4–9.7B drag, by category
% of national total
Reproductive & maternal
burden 9.2%·spend 1.1%·8.4× gap
Endometriosis & pelvic pain
burden 4.4%·spend 0.3%·14.7× gap
Cardiovascular (in women)
burden 11.8%·spend 2.9%·4.1× gap
Cancers (female-specific)
burden 7.1%·spend 4.2%·1.7× gap
Mental health (women)
burden 12.4%·spend 3.1%·4.0× gap
3.3%
Research $ to women-specific programs (FY2023–24)
$7.4–9.7B
Estimated annual GDP drag from under-addressed disease
4×
Median burden-to-spend gap in the categories above
The thesis
The Foundry is the operating layer. Capital rides on top — milestone-gated, co-invested, and governed by independent review.
Program shape — indicative
Cohort size
ventures per intake
6–8
Tranche sizes
per stage, per venture
$150k – $2M
Co-investment
strategic, institutional, philanthropic
Required
Governance
investment + clinical review committees
Independent
I
Women's health is under-translated, not just under-funded. The gap between discovery and patient impact is an operations problem with measurable economic consequences.
II
Specialist milestones, regulatory maps, and partner networks outperform generic incubation across every stage of the pipeline.
III
Tranches tied to decision-grade de-risking — not undifferentiated runway — produce better portfolio-level outcomes and clearer stop points.
IV
Public investment unlocks matched strategic, institutional and philanthropic capital. Built with universities, health services, industry and consumers as shared infrastructure.
The mechanism
Stage 02
Fund work that removes the next material uncertainties — technical, regulatory, commercial.
Deliverables
Typical funding
$150–400k
Duration
6–9 mo
What triggers advance
Why now, why us
The Foundry is the next scale of an operating platform already running. Staffing, selection process, review governance and partner network are in place — the mandate extends proven infrastructure to a specialist women's health cohort.
Operator track record
Proto Axiom has run translation programs across Australian universities and health services, attracting $19.5M+ in non-dilutive follow-on to portfolio teams and convening 950+ researchers, clinicians and industry partners through national programs.
$19.5M+
Non-dilutive follow-on
11
Teams incubated
950+
People convened
200+
Applications reviewed
Category specialism
Specialist milestones, endpoints and evidence sequencing. Category review embedded at selection, not bolted on. Designed with clinical and consumer partners across reproductive, cardiometabolic, oncology and mental-health programs.
4
Priority categories
14
Institutions engaged
4
States represented
100%
Consumer-reviewed selection
Mission fit
Moves Australian research through de-risking, evidence and commercialisation pathways into patient impact — directly addressing MRFF priorities around women's health, translation and the national research workforce. Co-investment structured for leverage, not substitution.
Co-invest
Required
Gated
Milestone capital
Independent
Review committees
National
Reach by design
Governance
Proto Axiom designs and runs the platform; investment decisions sit with an independent committee. Clinical and consumer advisory panels review category, evidence and ethics.
“Strong programs stall not because teams lack ambition, but because the next step is unclear. The Foundry exists to make the next step obvious.”
Independent. Meets each gate. Approves tranche advance, scope change, or stop.
Category experts. Review evidence plans and endpoint choices pre-funding.
Patients and advocates. Embedded in selection and design, not consulted post-hoc.
Builder-operator. Runs screening, incubation, and partner pathways day to day.
Why separation matters
Milestone capital is only credible if a body independent of the operating team can say “stop.” Investor, clinical and consumer review sit outside day-to-day operations by design.
Ecosystem
Organisations active in this space
Proto Axiom has worked with researchers and teams at many of these institutions. Formal platform partnerships are being established as governance settings are confirmed.
Insights
A 236-page history from Stifel's healthcare investment banking group lands as a bull thesis for the category Women's Health Foundry is built to serve. The signal matters more than the specifics — and Volume III, due later in 2026, is the one to watch.
6 min read
Australia has world-class research programs in reproductive biology, maternal health, and hormonal medicine. The challenge is converting that science into ventures that reach patients — and the infrastructure gap that sits between discovery and adoption.
10 min read
National platforms succeed when they strengthen — not bypass — universities, health services, industry, and investors. Shared milestones and governance-aware collaboration are how that works in practice.
6 min read
Register interest
We use this to prioritise outreach as the platform is finalised. Founders, partners, investors and community members each get a tailored brief.
Founders / researchers
Stage, category, and institution. We route to the right reviewer.
Partners / advisors
Sites, expertise, networks. Where you can contribute.
Investors / supporters
Tranches and timing. Updates on the anchor round.
Community / consumer
Lived experience and advocacy partners for review panels.